Gene-Disorder Association · Article
Gene
PCSK9 Proprotein Convertase Subtilisin/Kexin Type 9
×
First reported
2004
Supporting publications
48
Manually curated Approved treatment annotated
Association Review
In brief The association between PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) and Familial Hypercholesterolemia is well established and manually curated, with its 2 contributing sources — 1 of them expert-curated — recording pathogenic and likely-pathogenic variants.
Sources
2
Clinical variants
789
Symptoms
0
Compounds
5
Trials
18 of 165 via PCSK9 compounds
Publications
48
Contents
01
At a glance
Association overview A cited synthesis of the gene–disorder association, with a clinical-actionability summary where the evidence supports one.
Request access
02
Provenance
Evidence and sources 2 sources
Every contributing database and publication behind this association, with evidence type, strength, accessions and deep links.
Request access
1 source summary
A gene summary alongside the source descriptions it was distilled from.
Request access
04
Familial Hypercholesterolemia
The disorder 6 database identifiers
The disorder’s summary, prevalence, aliases and cross-reference identifiers (OMIM, Orphanet, MONDO, ICD-10, MedGen).
Request access
05
ClinVar and variant evidence
Genetic basis 789 clinical variants
ClinVar variants reported for this pair, with disorder-specific significance, review status, molecular consequence and origin.
Request access
06
Population genetics
GWAS signals 1 GWAS phenotype
Gene-associated GWAS phenotypes matching the disorder, with best SNP, score, risk-allele frequency and effect size.
Request access
07
Mechanism overlap
Shared mechanisms 1 shared pathway
Biological pathways and phenotype concepts shared by the gene and the disorder, with supporting publications.
Request access
08
Interventions
Therapeutics 5 compounds & drugs
Gene-targeting drugs and associated compounds, with class, approval status, mechanism, indications and trials.
Request access
09
Human studies
Clinical trials 165 clinical trials
Clinical trials reached through the pair’s compounds, keeping disorder-targeting trials separate from other indications.
Request access
48 publications
Publications linking the gene and the disorder, with title, authors, journal, year and citation metrics.
Request access
11
Provenance
References & sources 18 references
Every source and publication cited across this dossier, as one numbered reference list.
Request access